Momelotinib
Code | Size | Price |
---|
SYN-1035-M100 | 100 mg | Enquire |
Quantity:
SYN-1035-M001 | 1 mg | £104.00 |
Quantity:
SYN-1035-M005 | 5 mg | £139.00 |
Quantity:
SYN-1035-M010 | 10 mg | £197.00 |
Quantity:
SYN-1035-M050 | 50 mg | £537.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Images
Documents
Further Information
Alternate Names/Synonyms:
CYT387; Momelotinib
Appearance:
Solid.
CAS:
1056634-68-4
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
InChiKey:
ZVHNDZWQTBEVRY-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1056634-68-4. Formula: C23H22N6O2. MW: 414.5. CYT387 is selective inhibitor of JAK1 and JAK2 kinases including the JAK2V617F mutant . Using ATP kinase assays IC(50) values for JAK1 (11nm), JAK2, (18nM), JAK2, JAK2V617F (23nM) JAK3 (155nM), and TYK2 (17nM). In testing kinase arrays, CYT387 also had activity (defined as an IC(50) < 100nM) detected against CDK2/cyclin A, MAPK8 (JNK1), PRKCN (PKD3), PRKD1 (PKCµ), ROCK2, and TBK1 kinase as well.
Molecular Formula:
C23H22N6O2
Molecular Weight:
414.5
Package Type:
Plastic Vial
Product Description:
CYT387 is selective inhibitor of JAK1 and JAK2 kinases including the JAK2V617F mutant . Using ATP kinase assays IC(50) values for JAK1 (11nm), JAK2, (18nM), JAK2, JAK2V617F (23nM) JAK3 (155nM), and TYK2 (17nM). In testing kinase arrays, CYT387 also had activity (defined as an IC(50) < 100nM) detected against CDK2/cyclin A, MAPK8 (JNK1), PRKCN (PKD3), PRKD1 (PKCµ), ROCK2, and TBK1 kinase as well.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs): C.J. Burns, et al.; Bioorg. Med. Chem. Lett. 19, 5887 (2009) | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms: J.W. Tyner, et al.; Blood 115, 5232 (2010)
Related Products
Product Name | Product Code | Supplier |
---|